Laryngeal and hypopharyngeal cancers are prominent within head and neck malignancies. The diagnosis of distant metastasis (DM) invariably signals poor prognosis, underscoring the need to optimize current treatment approaches. Patient data for metastatic laryngeal and hypopharyngeal cancer were extracted from the SEER database (2000-2020). Cox regression and propensity score matching (PSM) analyses identified independent prognostic factors and performed stratified survival analyses based on the receipt of primary tumor surgery and radiotherapy. A random survival forest (RSF) model was subsequently developed to predict patient survival. A total of 1,626 patients were included. PSM-based stratified analysis revealed that primary tumor surgery significantly improved survival in patients under 70 years and those with primary laryngeal cancer. Radiotherapy enhanced survival across all age groups, with a benefit primarily for patients with primary laryngeal cancer and squamous-cell carcinoma (SCC). The RSF model demonstrated robust predictive performance, highlighting chemotherapy, primary tumor surgery, and radiotherapy as the top three factors influencing patient survival. The clinical and pathological features of metastatic laryngeal/hypopharyngeal cancer were systematically analyzed using an artificial intelligence (AI) model to predict survival. Subgroup analyses identified patients most likely to benefit from primary tumor surgery and radiotherapy. These findings may guide the development of personalized treatment strategies, potentially improving the prognosis of patients with DM.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11685675PMC
http://dx.doi.org/10.7150/jca.103793DOI Listing

Publication Analysis

Top Keywords

surgery radiotherapy
16
primary tumor
16
tumor surgery
16
laryngeal hypopharyngeal
12
random survival
8
survival forest
8
survival
8
survival patients
8
metastatic laryngeal
8
hypopharyngeal cancer
8

Similar Publications

Purpose Of Review: Male breast cancer (MBC) is a rare entity which often arises in elderly people. Aim of this review is to evaluate the principal issues related to MBC in elderly, because the therapeutic management of disease is not only related to the biological behavior of the tumor, but also to the comorbidities and frailty of older population. A scoping literature review was performed on Pubmed and Cochrane Database using the following keywords: therapeutic management/ male/ breast cancer/ elderly patients.

View Article and Find Full Text PDF

Efficacy and safety of KN026 and docetaxel for HER2-positive breast cancer: a phase II clinical trial.

Cancer Commun (Lond)

January 2025

Department of Medical Oncology, Cancer Hospital, Harbin Medical University, Harbin, Heilongjiang, P. R. China.

Background: The standard first-line treatment for human epidermal growth factor receptor 2 (HER2)-positive recurrent/metastatic breast cancer currently includes pertuzumab plus trastuzumab and docetaxel. This study aimed to evaluate the effectiveness of KN026, an anti-HER2 bispecific antibody, plus docetaxel in first-line treatment of HER2-positive recurrent/metastatic breast cancer.

Methods: This open-label, single-arm, phase II study enrolled patients with HER2-positive recurrent/metastatic breast cancer in 19 centers across China from December 30, 2019 to May 27, 2021.

View Article and Find Full Text PDF

Ultrasmall Au-GRHa Nanosystem for FL/CT Dual-Mode Imaging-Guided Targeting Photothermal Therapy of Ovarian Cancer.

Anal Chem

January 2025

State Key Laboratory of Supramolecular Structure and Materials, College of Chemistry, Jilin University, Changchun 130012, China.

As the most common and lethal cancer of the female gonads, ovarian cancer (OC) has a grave impact on people's health. OC is asymptomatic, insidious in onset, difficult to diagnose and treat, fast-growing, and easy to metastasize and has poor prognosis and high mortality. How to detect OC as early as possible and treat it without side effects has become a challenging medical problem.

View Article and Find Full Text PDF

The pro-tumor effects of mast cell (MC) in the tumor microenvironment (TME) are becoming increasingly clear. Recently, MC were shown to contribute to tumor malignancy by supporting the migration of tumor-associated macrophages (TAMs), suggesting a relationship with tumor immunity. In the current study, we aimed to examine the correlation between MC infiltration and neoadjuvant chemoradiotherapy (nCRT) response for locally advanced rectal cancer (LARC).

View Article and Find Full Text PDF

The important role of the histone acetyltransferases p300/CBP in cancer and the promising anticancer effects of p300/CBP inhibitors.

Cell Biol Toxicol

January 2025

Department of Ultrasound, Shengjing Hospital of China Medical University, 110004, Shenyang, Liaoning, China.

Histone acetyltransferases p300 (E1A-associated protein p300) and CBP (CREB binding protein), collectively known as p300/CBP due to shared sequence and functional synergy, catalyze histone H3K27 acetylation and consequently induce gene transcription. p300/CBP over-expression or over-activity activates the transcription of oncogenes, leading to cancer cell growth, resistance to apoptosis, tumor initiation and development. The discovery of small molecule inhibitors targeting p300/CBP histone acetyltransferase activity, bromodomains, dual inhibitors of p300/CBP and BRD4 bromodomains, as well as proteolysis-targeted-chimaera p300/CBP protein degraders, marks significant progress in cancer therapeutics.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!